17355-19-0

Basic information

• Product Name: L-Tyrosine,O-methyl-, methyl ester
• Synonyms: Alanine,3-(p-methoxyphenyl)-, methyl ester (6CI); (L)-Methyl 4-methoxyphenylalaninate;O-Methyltyrosine methyl ester
• CAS NO: 17355-19-0
• Molecular Formula: C11H15 N O3
• Molecular Weight: 209.245
• Mol File: 17355-19-0.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: L-Tyrosine,O-methyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Tyrosine,O-methyl-, methyl ester(17355-19-0)
• EPA Substance Registry System: L-Tyrosine,O-methyl-, methyl ester(17355-19-0)

Safety Data

• Hazardous Substances Data: 17355-19-0(Hazardous Substances Data)

Usage

General Description

L-Tyrosine, O-methyl-, methyl ester is a chemical compound that is a derivative of the amino acid tyrosine. It is commonly used as a precursor in the synthesis of various neurotransmitters, including dopamine, epinephrine, and norepinephrine. It is also known for its potential role in the production of thyroid hormones and melanin. L-Tyrosine, O-methyl-, methyl ester has been studied for its potential benefits in promoting cognitive function, improving mood, and enhancing physical performance. It is commonly used as a dietary supplement and is generally considered safe when taken at recommended doses. However, it should be used with caution by individuals with certain medical conditions or when taking other medications.

Upstream product

• 75105-81-6 N,N-diallyl-OMe-L-tyr-OMe 
• 94790-24-6 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoate 
• 53267-93-9 O-methyl-N-tert-butoxycarbonyl-L-tyrosine 
• 94790-24-6 (2R)-tert-butoxycarbonylamino-3-(4-methoxyphenyl)propionic acid methyl ester 
• 67-56-1 methanol 
• 39878-65-4 (R)-β-(4-methoxyphenyl)alanine 
• 3728-20-9 D-tyrosine methylester hydrochloride 
• 556-02-5 tyrosine 
• 76757-90-9 N-(tert-butoxycarbonyl)-D-tyrosine methyl ester 
• 70601-63-7 (D)-4-methoxyphenylalanine hydrochloride 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 3978-80-1 Boc-Tyr-OH 
• 53796-61-5 N-acetyl-O-methyl-tyrosine 
• 162780-24-7 (S)-3-Benzyl-4-(4-methoxy-benzyl)-oxazolidine-2,5-dione 

Downstream Products

• 94790-24-6 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoate 
• 75105-81-6 N,N-diallyl-OMe-L-tyr-OMe 
• 20046-34-8 (N-Carbamoyl-S-benzyl-Cys)-(O-methyl-Tyr)-methylester 
• 122225-35-8 (S)-2-(6-tert-Butoxycarbonylamino-hexanoylamino)-3-(4-methoxy-phenyl)-propionic acid methyl ester 
• 52177-38-5 α-isocyanato-L-O-methyltyrosine methyl ester 
• 291781-64-1 (S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(4-fluoro-3-nitro-phenyl)-propionylamino]-3-(4-methoxy-phenyl)-propionic acid methyl ester 
• 327037-77-4 (S)-2-{(S)-3-(4-Hydroxy-phenyl)-2-[methyl-(4-nitro-benzenesulfonyl)-amino]-propylamino}-3-(4-methoxy-phenyl)-propionic acid methyl ester 
• 570383-53-8 methyl (2S,5S)-5-(N-tert-butoxycarbonyl-N-methylamino)-2-(4-methoxyphenyl)methyl-6-(4-oxocyclohex-1-enyl)-3-azahexanoate ethylene acetal 
• 121778-71-0 (S)-2-(benzyloxycarbonylamino)-3-(4-methoxyphenyl)-1-propionic acid methyl ester 
• 20989-19-9 (2S)-2-amino-3-(4-methoxyphenyl)propan-1-ol 

Relevant articles and documents

Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. Anti-trypanosomal activity against the CL Brener strain of T. cruzi was observed in the 0.1 μM to 1 μM range for three nitrile-based cysteine protease inhibitors based on two scaffolds known to be associated with cathepsin K inhibition. The two compounds showing the greatest potency against the trypanosome were characterized by EC50values (0.12 μM and 0.25 μM) that were an order of magnitude lower than the corresponding Kivalues measured against cruzain, a recombinant form of cruzipain, in an enzyme inhibition assay. This implies that the anti-trypanosomal activity of these two compounds may not be explained only by the inhibition of the cruzain enzyme, thereby triggering a putative polypharmacological profile towards cysteine proteases.

Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20s proteasome inhibitors

Proteasome inhibitors are promising compounds for a number of therapies, including cardiovascular and eye diseases, diabetes, and cancers. We previously reported a series of furanbased peptidic inhibitors with moderate potencies against the proteasome b5 subunit, hypothesizing that the C-terminal furyl ketone motif could form a covalent bond with the catalytic residue, threonine 1. In this context, we describe further optimizations of the furan-based peptides, and a series of dipeptidic and tripeptidic inhibitors were designed and synthesized, aiming at improved potency and better solubility. Most of the tripeptidic inhibitors demonstrated improved potency and selectivity as b5 subunit inhibitors in both enzymatic and cellular assays, and good antineoplastic activities in various tumor cell lines were also observed. However, no inhibitory effects were observed for the dipeptidic compounds, which led us to presume that a noncovalent binding mode is adopted. Docking studies and molecular dynamics simulations were carried out to verify this presumption, with results showing that the distance between the furyl ketone motif and Thr1 is slightly too long to form covalent bond.

OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS

The present invention relates to novel compounds derived from oxoazetidine corresponding to general formula (I) to the compositions containing same, to the process for preparation thereof and to the use thereof in pharmaceutical or cosmetic compositions.